Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis

the International Prophylaxis Study Group (IPSG)

doi:10.1111/hae.13558

Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis

the International Prophylaxis Study Group (IPSG)

Research output: Contribution to journal › Comment/debate

6 Scopus citations

Original language	English
Pages (from-to)	845-848
Number of pages	4
Journal	Haemophilia
Volume	24
Issue number	6
DOIs	https://doi.org/10.1111/hae.13558
State	Published - Nov 2018

Access to Document

10.1111/hae.13558

Cite this

@article{bc4609f469ee48bd9e065390576410b3,

title = "Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis",

author = "\{the International Prophylaxis Study Group (IPSG)\} and M. Carcao and T. Lambert and C. Leissinger and C. Escuriola-Ettingshausen and E. Santagostino and L. Aledort",

note = "Funding Information: We wish to thank Drs. Victor Blanchette (Chair of the IPSG Executive) and Rolf Ljung (member of the IPSG Executive) for their careful review of our manuscript and for providing helpful suggestions. Funding Information: Manuel Carcao reports having received research support from Bayer, Bioverativ/Sonofi, CSL-Behring, Novo Nordisk, Octapharma, Pfizer and Shire. He has also received honoraria for speaking/participating in advisory boards from Bayer, Bioverativ/ Sonofi, Biotest, CSL Behring, Grifols, LFB, Novo Nordisk, Octapharma, Pfizer, Roche and Shire. Thierry Lambert has served on advisory boards for: Bayer, CSL-Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Shire and Sobi. Cindy Leissinger reports having served on advisory boards for the following: Bayer, CSL-Behring, Kedrion, Novo Nordisk, Octapharma, Shire and additionally she has received research funding from Roche. Carmen Escuriola-Ettingshausen received honoraria for speaking/participating in advisory boards from Alnylam, Biotest, CSL Behring, Freeline, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche and Shire. Elena Santagostino has served on advisory boards and/or speaker bureaus for: Bayer, CSL-Behring, Kedrion, Novo Nordisk, Octapharma, Shire, Roche, Pfizer, Grifols, Sobi and Biogen. Louis Aledort has served on advisory boards to Kedrion and Shire; has Chaired a Data Safety Monitoring Board for Octapharma and has received honoraria/speaking fees from Bayer. The International Prophylaxis Study Group (IPSG) is a not for profit Study Group that is supported by grants from Bayer Healthcare, Bioverativ-Sonofi, CSL-Behring, Novo Nordisk, Pfizer and Shire to the Hospital for Sick Children (“SickKids”) Foundation in support of the IPSG. None of the members of the Prophylaxis Expert Working Group receive remuneration for their contributions to the IPSG.",

year = "2018",

month = nov,

doi = "10.1111/hae.13558",

language = "English",

volume = "24",

pages = "845--848",

journal = "Haemophilia",

issn = "1351-8216",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Prophylaxis re-visited

T2 - The potential impact of novel factor and non-factor therapies on prophylaxis

AU - the International Prophylaxis Study Group (IPSG)

AU - Carcao, M.

AU - Lambert, T.

AU - Leissinger, C.

AU - Escuriola-Ettingshausen, C.

AU - Santagostino, E.

AU - Aledort, L.

N1 - Funding Information: We wish to thank Drs. Victor Blanchette (Chair of the IPSG Executive) and Rolf Ljung (member of the IPSG Executive) for their careful review of our manuscript and for providing helpful suggestions. Funding Information: Manuel Carcao reports having received research support from Bayer, Bioverativ/Sonofi, CSL-Behring, Novo Nordisk, Octapharma, Pfizer and Shire. He has also received honoraria for speaking/participating in advisory boards from Bayer, Bioverativ/ Sonofi, Biotest, CSL Behring, Grifols, LFB, Novo Nordisk, Octapharma, Pfizer, Roche and Shire. Thierry Lambert has served on advisory boards for: Bayer, CSL-Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Shire and Sobi. Cindy Leissinger reports having served on advisory boards for the following: Bayer, CSL-Behring, Kedrion, Novo Nordisk, Octapharma, Shire and additionally she has received research funding from Roche. Carmen Escuriola-Ettingshausen received honoraria for speaking/participating in advisory boards from Alnylam, Biotest, CSL Behring, Freeline, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche and Shire. Elena Santagostino has served on advisory boards and/or speaker bureaus for: Bayer, CSL-Behring, Kedrion, Novo Nordisk, Octapharma, Shire, Roche, Pfizer, Grifols, Sobi and Biogen. Louis Aledort has served on advisory boards to Kedrion and Shire; has Chaired a Data Safety Monitoring Board for Octapharma and has received honoraria/speaking fees from Bayer. The International Prophylaxis Study Group (IPSG) is a not for profit Study Group that is supported by grants from Bayer Healthcare, Bioverativ-Sonofi, CSL-Behring, Novo Nordisk, Pfizer and Shire to the Hospital for Sick Children (“SickKids”) Foundation in support of the IPSG. None of the members of the Prophylaxis Expert Working Group receive remuneration for their contributions to the IPSG.

PY - 2018/11

Y1 - 2018/11

UR - https://www.scopus.com/pages/publications/85050483275

U2 - 10.1111/hae.13558

DO - 10.1111/hae.13558

M3 - Comment/debate

C2 - 29989273

AN - SCOPUS:85050483275

SN - 1351-8216

VL - 24

SP - 845

EP - 848

JO - Haemophilia

JF - Haemophilia

IS - 6

ER -